Management of Dyslipidemia Associated with Anti-Retroviral Therapy in HIV/AIDS Patients

• Main Authors: Debrina Kusuma Devi, Erwin Astha Triyono, Musofa rusli
• Format: Book Section PeerReviewed
• Language: English; English; English
• Published: Scitepress 2017
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: http://repository.unair.ac.id/96484/1/Management%20of%20Dyslipidemia%20Associated%20with%20Anti-Retroviral%20Therapy%20in%20HIVAIDS%20Patients.pdf; http://repository.unair.ac.id/96484/2/Management%20of%20Dysplidemia.pdf; http://repository.unair.ac.id/96484/3/Management%20of%20Dyslipidemia%20Associated%20with%20Anti-Retroviral%20Therapy%20in%20HIV_AIDS%20Patients.pdf; http://repository.unair.ac.id/96484/; https://www.scitepress.org/PublicationsDetail.aspx?ID=1y4gz8M8xVg=&t=1
• Institution: Universitas Airlangga

Dyslipidemia is a lipid metabolism disorder characterized by increased and decreased lipid fractions in plasma, including elevated total cholesterol, low-density lipoprotein (LDL) cholesterol, TG, and decreased HDL cholesterol. Dyslipidemia often occurs in patients with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), especially those who have received anti-retroviral therapy (ARV). Various ARVs can cause dyslipidemia and the most common is the Protease Inhibitor group. Dyslipidemia is an important risk factor for cardiovascular events. Management of dyslipidemia in HIV-infected patients receiving antiretroviral therapy includes lifestyle modification, switching of antiretroviral drugs, and the use of lipid-lowering drugs as targeted by the recommendations of the NCEP ATP III